       Document 0712
 DOCN  M9640712
 TI    Seroconversion to HBV associated with seroconversion to HIV in a cohort
       of intravenous drug misusers in Turin, Italy.
 DT    9604
 AU    Sinicco A; Fora R; Sciandra M; Raiteri R; Institute of Infectious
       Diseases, University of Turin, Italy.
 SO    Eur J Epidemiol. 1995 Oct;11(5):535-9. Unique Identifier : AIDSLINE
       MED/96139647
 AB    Between March 1986 and March 1994, the seroconversion to HBV associated
       to the seroconversion to HIV was investigated in 120 HIV seroconverters
       drawn from 2368 i.v. drug misusers screened for HIV, HBV and STDs. Among
       the 185 individuals susceptible to HIV and HBV at intake (41/120 HIV
       seroconverters and 144/364 HIV-negative controls), HBV seroconversion
       was associated with the seroconversion to HIV (p = 0.006) and history of
       more than 3 sexual partners per year (p = 0.000). Only the history of
       more than 3 partners per year remained associated with the HBV
       seroconversion in the conditional regression. The associated
       seroconversion to HIV and HBV was linked to the short period of i.v.
       drug injections (p = 0.032), history of more than 3 partners per year (p
       = 0.000) and more than 3 i.v. drug injections per day (p = 0.016).
       Compared to the seroconverters to HBV alone, the seroconverters to HBV
       and HIV were likely to have higher frequency of i.v. drug injection per
       day on univariate (p = 0.031) and multivariate analysis (p = 0.024). The
       seroconverters to both the viruses differed from the seroconverters to
       HIV alone in the year of drug debut (p = 0.045), short period of i.v.
       drug use (p = 0.048) and high frequency of injection per day (p =
       0.008). The multivariate analysis confirmed only the association with
       high frequency of injection per day (p = 0.033). Higher risk of HIV
       seroconversion from the debut of i.v. drug use was observed in the
       subjects with concurrent HBV seroconversion (Log-Rank test: p = 0.0008).
 DE    Adult  Cohort Studies  Comorbidity  Comparative Study  Disease
       Susceptibility  Female  Hepatitis B/EPIDEMIOLOGY/TRANSMISSION  Hepatitis
       B Antibodies/*BLOOD  Human  HIV Antibodies/*BLOOD  HIV
       Infections/EPIDEMIOLOGY/TRANSMISSION  HIV Seropositivity/*EPIDEMIOLOGY
       HIV Seroprevalence  Italy/EPIDEMIOLOGY  Male  Multivariate Analysis
       Regression Analysis  Risk Factors  Seroepidemiologic Methods  Sexual
       Partners  *Substance Abuse, Intravenous/EPIDEMIOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

